SCP0153
GLP-1 (Preproglucagon 72-107 amide) (GLP-1 human)
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
Empirical Formula (Hill Notation):
C184H273N51O57
Molecular Weight:
4111.44
UNSPSC Code:
12352200
NACRES:
NA.32
Recommended Products
Assay
≥95% (HPLC)
form
lyophilized
composition
Peptide Content, ≥75%
storage condition
protect from light
storage temp.
−20°C
Amino Acid Sequence
His-Asp-Glu-Phe-Glu-Arg-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-NH2
Application
GLP-1 (Preproglucagon 72-107 amide) (GLP-1 human) has been used to study its effect on vascular endothelial growth factor-A (VEGFA)-mediated endothelium-dependent signaling and vasodilation.
Glycogen-like peptide-1 (GLP-1) is an amino acid peptide derived from proglucogon. GLP-1 is involved in the regulation of the glycemic index via its affect on glucagon and insulin levels. GLP-1 may be used to study its interaction with its receptor, the GLP-1 receptor.
Biochem/physiol Actions
Glycogen-like peptide-1 (GLP-1) is an insulinotropic hormone, which takes part in increasing insulin secretion and insulin sensitivity. It also inhibits the secretion of glycogen and reduces fasting glucose levels.
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
GLP-1 inhibits VEGFA-mediated signaling in isolated human endothelial cells and VEGFA-induced dilation of rat mesenteric arteries
Egholm C, et al.
American Journal of Physiology. Heart and Circulatory Physiology, 311(5), H1214-H1224 (2016)
Voglibose: an alpha-glucosidase inhibitor
Dabhi AS, et al.
Journal of Clinical and Diagnostic Research : JCDR, 7(12), 3023-3023 (2013)
Alaa Al Helaili et al.
Biochemical and biophysical research communications, 533(1), 110-117 (2020-09-19)
Dysfunction of the gut-brain axis is one of the potential contributors to the pathophysiology of obesity and is therefore a potential target for treatment. Vagal afferents innervating the gut play an important role in controlling energy homeostasis. There is an
Fan Xiao et al.
Frontiers in cardiovascular medicine, 8, 709741-709741 (2021-09-14)
Objectives: This study explores the concentration and role of glucagon-like peptide-1 (GLP-1) in calcific aortic valve disease (CAVD). Background: Calcific aortic valve disease is a chronic disease presenting with aortic valve degeneration and mineralization. We hypothesized that the level of
Cecilie Egholm et al.
American journal of physiology. Heart and circulatory physiology, 311(5), H1214-H1224 (2016-11-03)
We investigated the acute effects of glucagon-like peptide-1 (GLP-1), GLP-1(1-36), and GLP-1(7-36) on vascular endothelial growth factor-A (VEGFA)-induced endothelium-dependent signaling and vasodilation. Our hypothesis was that GLP-1 released from intestinal l-cells modulates processes related to PLCγ activation, Src, and endothelial
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service